Breaking News! Under NPA’s Pressure, FDA Announces NMN is Lawful for Use in Dietary Supplements

Editor’s Note
For Chinese consumers, this news is particularly important. The FDA’s latest decision confirms NMN’s legal status as a dietary supplement in the United States. This not only strengthens consumer confidence in NMN products, but also provides a clearer regulatory environment for industry growth. Looking ahead, as international markets become more standardized, NMN is expected to reach global consumers in a more compliant and transparent way.

September 29, 2025 — After nearly three years of continuous pressure from the Natural Products Association (NPA), the U.S. Food and Drug Administration (FDA) has finally reversed its stance and confirmed that β-Nicotinamide Mononucleotide (NMN) can be lawfully used in dietary supplements.

Previously, the FDA attempted to block NMN from entering the supplement market on the grounds that the ingredient was initially studied as a new drug. NPA rejected this explanation, filing a citizen petition with the FDA, launching a federal lawsuit against the agency in Washington, D.C., and mobilizing both the industry and consumers to challenge the FDA. In response, the FDA acknowledged evidence showing that NMN had already been marketed in the U.S. as a dietary supplement as early as 2017, and therefore should not be excluded from the definition of a dietary supplement.

In its response to the citizen petition, the FDA further elaborated on its interpretation of the “drug exclusion clause” or “prior drug exclusion” under the Dietary Supplement Health and Education Act (DSHEA) of 1994. While the NPA continues to disagree with parts of the FDA’s legal reasoning, the association welcomed the FDA’s reconsideration of its position.

💬 NPA President and CEO, Dr. Daniel Fabricant, stated:
“Today’s FDA decision confirms that NMN is lawful in supplements, and we now call on e-commerce platforms to immediately reinstate the sale of NMN products. We will continue to press Congress, the courts, and the administration until the FDA fully stops its abuse of the drug exclusion clause.”

In fact, this is not the first time the FDA has reversed its position under NPA’s actions. In 2022, after NPA filed petitions and lawsuits challenging FDA’s attempt to exclude NAC (N-Acetyl-L-Cysteine) from the supplement market, the FDA ultimately issued an “enforcement discretion policy” allowing NAC products back into the market.

As NPA approaches its 90th anniversary in 2026, this NMN victory once again highlights the association’s influence in holding the FDA accountable and defending consumer choice.